Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Red Brewer

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Discovery|February 10, 2019
Correction: An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Discovery|March 10, 2017
An Acquired <i>HER2</i><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Cell|February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Science Signaling|March 31, 2016
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitorsSizhi P Gao, Qing Chang, Ninghui Mao, et al.
Cancer Cell|January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migrationDaniel J Zabransky, Christopher L Yankaskas, Rory L Cochran, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Nature Medicine|November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine|September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Discovery|February 10, 2019
Correction: An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Discovery|March 10, 2017
An Acquired <i>HER2</i><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Cell|February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Science Signaling|March 31, 2016
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitorsSizhi P Gao, Qing Chang, Ninghui Mao, et al.
Cancer Cell|January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migrationDaniel J Zabransky, Christopher L Yankaskas, Rory L Cochran, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Nature Medicine|November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine|September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerChristine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Pageof 2